Schizophrenia Clinical Trials in West Palm Beach
View 28 new treatments for Schizophrenia in West Palm Beach, FL. Every day, Power helps hundreds of Schizophrenia patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Vortioxetine for Schizophrenia
Research Clinic, Lauderdale Lakes + 1 more
This is a 16-week, randomized, double-blind, parallel group, placebo-controlled study comparing adjunctive vortioxetine with identically appearing adjunctive placebo pills in 88 stable patients with a research diagnosis of schizophrenia determined with the Structured Clinical Interview for DSM (SCID). Patient randomization will be stratified by illness duration (i.e., \</=5 years and \>5 years) in order to allow for post-hoc analyses examining whether earlier illness moderates greater negative and /or cognitive symptom reduction in response to vortioxetine.Show More
Waitlist
Phase 4
Est. 4 - 6 Weeks
Christoph U Correll, MD
Principal Investigator
KarXT for Schizophrenia
Karuna Clinic, Lauderhill + 1 more
This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Ronald Marcus, MD
Study Director
Long-term Safety of Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Hollywood + 1 more
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Brilaroxazine for Schizophrenia
Reviva Clinic, Hollywood + 1 more
This trial tests Brilaroxazine, a daily pill, in patients with severe mental health issues. It aims to improve mood and reduce symptoms. The study lasts for more than a year.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Medical Director
Study Director
SEP-363856 for Schizophrenia
Sunovion Clinic, Hollywood + 1 more
This trial is testing a new schizophrenia medication called SEP-363856 in people who have already started using it. The goal is to see if it is safe and effective over several months. The medication works by affecting brain chemicals to help reduce symptoms of schizophrenia.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
CNS Medical Director
Study Chair
KarXT for Schizophrenia
Karuna Clinic, Tamarac + 2 more
This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Bristol-Myers Squibb
Study Director
Dexmedetomidine for Agitation in Schizophrenia and Bipolar Disorder
BioXcel Clinic, Oakland Park + 1 more
In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Robert Risinger, MD
Study Chair
Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Hollywood + 1 more
This trial is testing a new medicine called iclepertin to see if it can help adults with schizophrenia improve their learning and memory. Participants will take either the medicine or a non-active substance while continuing their regular medication. Doctors will regularly check their mental abilities and overall health over several months.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Valbenazine for Schizophrenia
Neurocrine Clinic, West Palm Beach + 1 more
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Clinical Development Lead
Study Director
TV-44749 for Schizophrenia
Teva Branded Clinic, Hollywood + 1 more
This trial is testing a new medication called TV-44749 to see if it helps adults with schizophrenia, especially those with worsening symptoms. The medication likely works by balancing brain chemicals to reduce symptoms. The study will last over a year, with different phases to test both its effectiveness and safety.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Teva Medical Expert, MD
Study Director
Page 1 of 2
Frequently Asked Questions
Explore related conditions